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This study investigated the antioxidant system response of male reproductive organs during early and late phases of diabetes and
the influence of melatonin treatment. Melatonin was administered to five-week-old Wistar rats throughout the experiment, in
drinking water (10 𝜇g/kg b.w). Diabetes was induced at 13 weeks of age by streptozotocin (4.5mg/100 g b.w., i.p.) and animals
were euthanized with 14 or 21 weeks old. Activities of catalase (CAT), glutathione-S-transferase (GST), glutathione peroxidase
(GPx), and lipid peroxidation were evaluated in prostate, testis, and epididymis. The enzymes activities and lipid peroxidation
were not affected in testis and epididymis after one or eight weeks of diabetes. Prostate exhibited a 3-fold increase in GPx activity
at short-term diabetes and at long-term diabetes there were 2- and 3-fold increase in CAT and GST, respectively (𝑝 ≤ 0.01).
Melatonin treatment to healthy rats caused a 47% increase in epididymal GPx activity in 14-week-old rats. In prostate, melatonin
administration normalizedGST activity at both ages andmitigatedGPx at short-term andCAT at long-term diabetes.The testis and
epididymis were less affected by diabetes than prostate. Furthermore, melatonin normalized the enzymatic disorders in prostate
demonstrating its effective antioxidant role, even at low dosages.
1. Introduction
Diabetes mellitus (DM) affects 8.3% of the world population
and approximately 5.1 million people aged between 20 and
79 years died from diabetes in 2014 [1]. The high mortality
and negative impact of diabetes on life quality are due to
the progressive impairment ofmultiple organ systems, caused
mainly by hyperglycemia and oxidative stress [2]. The oxida-
tive status in diabetes is due to impairment of mitochondrial
electron transfer, the activation of polyol pathways, the catal-
ysis of cyclooxygenase intermediate products, and enhanced
nonenzymatic glycation [3–5]. In turn, advanced glycation
end-products (AGE) produced by nonenzymatic glycation
lead to the generation of reactive oxygen species (ROS),
the activation of Bax, and expression of proapoptotic and
proinflammatory genes, such as c-Jun N-terminal kinase [2,
6, 7]. Thus, as confirmed by cDNA microarray analysis, dia-
betes can alter the expression of multiple genes, particularly
those related to cell proliferation and differentiation, oxida-
tive stress biomarkers, DNAdamage repair, and apoptosis [8].
The vast majority of patients with type 1 DM are diag-
nosed before the age of 30 and amodest excess of cases occurs
in males [9] where its negative influence on reproductive
function is relevant. Clinical evidence indicates that diabetes
is associated with multiple impairment of male genital phys-
iology, such as reduced androgen levels, erectile dysfunction,
retrograde ejaculation, poor semen quality, and reduced
fertility [10, 11]. Diabetes has also been associated with an
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increased risk of numerous cancers, but the data concerning
prostate cancer are inconsistent [12, 13]. Most evidence,
including ameta-analysis [14] of 19 studies published between
1971 and 2005, has indicated an inverse correlation between
diabetes and prostate cancer [15, 16].
Most clinical data concerning the negative impact of
diabetes on male reproductive physiology have been cor-
roborated by experimental models of induced diabetes [17–
25]. The influence of oxidative stress due to diabetes on the
response of different genital organs has been previously inves-
tigated in rats [26–32]. However, information concerning
how these changes occur during disease progression is scarce.
Theneurohormonemelatonin (N-acetyl-5-methoxytryp-
tamine) is secreted rhythmically following a periodicity
that is controlled by a circadian pacemaker located in the
suprachiasmatic nucleus [33]. Melatonin (MLT) regulates
several physiological functions, according to the light-dark
daily cycle. It has been suggested that the rhythmicity of
MLT action also controls the activity and gene expression
of antioxidant enzymes [34]. MLT and its metabolites,
N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK), and
N1-acetyl-5-methoxykynuramine (AMK) exhibit antioxidant
activities that are related to the direct removal of hydroxyl
radicals, nitric oxide, and peroxynitrite anions acting as free
radical scavengers [35–38]. A few studies using cultured cells
indicate that melatonin promoted the generation of ROS
at pharmacological concentrations; however its prooxidant
action in vivo remains to be elucidated [39]. Experimental
evidence has shown that administration of MLT at doses of
5mg to 150mg/kg body weight ameliorates the oxidative sta-
tus in the pancreas, liver, heart, kidneys, and testis [26, 40, 41].
Besides, the administration of low doses of MLT (25𝜇g/mL)
to rats fed with high fat-diet showed that this hormone was
able to normalize the altered biochemical proinflammatory
profile in these animals [42]. The consequences of MLT
consumption at low doses during sexual maturation of the
male genital organs and their oxidative status at adulthood
are unknown. In addition, considering that MLT interferes
with androgen production and affects androgen-dependent
organs, which also occurs in diabetes, more information is
necessary to better discriminate the putative and protective
role of exogenous MLT in genital organs under diabetes
and also to delineate the response of organs during disease
progression. Thus, this study comparatively examined the
early and advanced responses of the antioxidant system in
rat male genital organs subjected to experimental diabetes
and the influence of low MLT dose treatment prior to and
concomitant with the disease in these systems.
2. Material and Methods
2.1. Experimental Design. Eighty male Wistar rats (Rattus
norvegicus) were obtained from the breeding house of Sa˜o
Paulo State University (Botucatu, SP, Brazil). All experi-
ments were performed in accordance with the Guide for
the Care and Use of Laboratory Animals published by the
US National Institutes of Health and acknowledged by the
institutional ethical committee for animal experimentation
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Figure 1: Experimental design of the study. Melatonin was offered
in the drinking water (10𝜇g/kg b.w), and diabetes was induced
by streptozotocin injection (4.5mg/100 g b.w., i.p.). C1: one-week
control; M1: one-week control treated with melatonin; D1: one-
week diabetic; MD1: one-week diabetic treated with melatonin; C2:
two-month control; M2: two-month control treated withmelatonin;
D2: two-month diabetic; MD2: two-month diabetic treated with
melatonin (𝑁 = 10 animals/group). The euthanasia was performed
at 13 weeks of age for short-term experiment and at 21 weeks of age
for long-term experiment.
(Protocol number 051/2011-CEEA).The animals were kept in
polyethylene cages with wood shavings in a 12 : 12 light/dark
cycle, at a temperature of about 22∘C and with free access
to food (Presence, Invivo, Paulinia, SP, Brazil) and filtered
water. After an adaptation period, the rats were weighed
and randomly distributed into eight groups (Figure 1, 𝑁 =
10 per group). The short-term experiment consisted of a
control (C1), a control treated with MLT (M1), one-week-
diabetic rats (D1), and one-week-diabetic rats treated with
MLT (MD1).The long-term experiment consisted of a control
(C2), a control treated with MLT (M2), two-month diabetic
rats (D2), and two-month diabetic rats treated with MLT
(MD2). The administration of MLT (Sigma Chemical Co.,
St Louis, MO, USA) followed the procedures established by
Wolden-Hanson et al. [43]. This hormone was dissolved in
ethanol and stored in aliquots at −70∘C. Rats in groups M1,
M2, MD1, and MD2 were provided with MLT from five to
14 weeks of age, via drinking water (10 𝜇g/kg body weight
in ethanol 0.001%/day). The MLT intake per day in this
investigation was based on mean daily water consumption of
80mL/day/animal and a mean body weight of 350 g and was
available to the animals in plastic bottles protected from light.
These conditions were standardized by the application of
various consumption preference and aversion tests; therefore,
this is an appropriate dosage for the induction of increased
MLT levels during the night [43].
Diabetes was induced in untreated (groups D1 and
D2) and MLT-treated (groups DM1 and DM2) rats aged
13 weeks. After 24 h fasting, animals were anesthetized
(0.1mL ketamine and 0.1mL xylazine/100 g body weight) and
injected intraperitoneally with 4.5mg/100 g body weight of
streptozotocin (Sigma, St. Louis,MO,USA), diluted in 0.01M
citrate buffer, pH 4.5. The control animals were injected only
with citrate buffer. The blood glucose levels were evaluated
two days after streptozotocin injection, in the tips of the paws
using the glucose monitor Accu-chek (Roche Diagnostics,
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Mannheim, Germany). Only animals that showed blood
glucose levels above 220mg/dL were included in the diabetic
groups. Because water consumption is higher for diabetic
animals, theMLTdosewas corrected for groupsD1,D2,MD1,
andMD2 following the diagnosis of diabetes.The C1, M1, D1,
andMD1 groupswere euthanizedwhenwith 14weeks old and
the C2, M2, D2, and MD2 groups were euthanized when 21
weeks old.The ratswere euthanized usingCO
2
inhalation and
were subsequently decapitated for blood collection.
2.2. Activity of Antioxidant Enzymes. The antioxidant
enzyme activity of all animals was assayed in the ventral
prostate, testis, and epididymis and also in blood.After dissec-
tion, these organs were weighed and homogenized in 1 : 4
volume of buffer with protease inhibitors (50mM Tris-HCl,
1mM EDTA, 1mM DTT, 0.5M sucrose, and 0.15M KCl,
1mM PMSF, pH 7.4) and centrifuged at 10.000 g for 20min
at 4∘C. The supernatant was then recentrifuged at 50.000 g
for another 60min at 2∘C and the supernatant fraction was
removed and was used to measure the activity of catalase
(CAT), glutathione-S-transferase (GST), and glutathione
peroxidase (GPx).
The blood samples were collected in polyethylene tubes
containing EDTA immediately after decapitating the animals.
For the determination of CAT activity, the blood samples
were diluted 50 times in distilled water, whereas for the
determination of GPx and GST activities, blood was diluted
20 times in a hemolyzing solution (7mM 2-mercaptoetanol;
2mM NADP; 0.27M EDTA).
The CAT activity was quantified at 240 nm for 1min by
the decomposition of 10 nmH
2
O
2
[44].The total GST activity
was determined by measuring the increase in absorbance
at 340 nm for 1min 40 s by an assay containing reduced
glutathione (200mMGSH) and 1-chloro-2,4-dinitrobenzene
(200mM CNDB) as substrates, according to Keen et al. [45].
The total GPx activity was evaluated by NADPH (0.2M)
oxidation, concomitant with GSSG reduction by excess
glutathione reductase, causing a decrease in absorbance at
340 nm for 1min, according to Sies et al. [46]. All tests were
performed at room temperature. The total protein content
(mg/mL) in the samples was determined using bovine serum
albumin as a standard, by the modified Lowry method [47].
The specific molar extinction constant (𝜀) was used to esti-
mate the levels of enzyme activity in U/mg protein (𝜀 = 0.071
for CAT, 𝜀 = 6.22 for GPx, and 𝜀 = 9.6 for GST).The equation
used for enzymatic activity was [Absorbance variation ×
1000/𝜀 × sample volume (𝜇L)/total protein concentration of
the sample (mg/mL)].
2.3. Determination of Lipid Peroxidation Levels. The levels
of lipid peroxidation were evaluated in the same organs
and in blood, by the quantification of malondialdehyde
(MDA) levels, an indicator of oxidation. For this, the presence
of the colored derivative formed between MDA and 2-
thiobarbituric acid (TBA) was detected via HPLC at 532 nm
[48]. Quantification of MDA in the tissues was performed
with 100 𝜇L of homogenized tissue in buffer (1 : 4 v/v) and
100–200𝜇L of plasma. Three hundred 𝜇L of 0.4% thiobar-
bituric acid solution (diluted in 0.2MHCl) was added to
the tissue and plasma samples and they were incubated for
40min at 90∘C in a dry block. The samples of TBA-MDA
were extracted with 1mL n-butanol and centrifuged at 890 g
for 3min at 3∘C. TBA-MDA (20𝜇L) samples were directly
injected in HPLC and monitored at 532 nm. The mobile
phase consisted of 50 nM monobasic phosphate potassium
solution, pH 7.0, 20% methanol, and a pumped isocratic
flow of 1.0mL/min. The HPLC system (Shimadzu) consisted
of two LC-10ADVP pumps, a SPD-M10ADVP UV-visible
detector, and a SCL-10AVP controller and a LC-18 (150 ×
4.6mm, 5𝜇m pore diameter) column was used. The MDA
estimation was based on a standard calibration curve of
tetramethoxypropane (TMP) previously prepared using the
same procedure as that used for samples. The data were
expressed as nmol/mg tissue and 𝜇mol/mL plasma. The
equation to calculate the amount of MDA in samples was
(peak area/slope of calibration curve)/C, C = [sample volume
(𝜇L) × injection volume (𝜇L))/1000 𝜇L of n-butanol].
2.4. Statistical Analysis. Statistical analyses were performed
among groups of the same experimental period (multiple
comparison tests) and between both experimental periods
for the same treatment (paired difference tests) using the
Statistica 9.0 software (Statsoft Inc., Tulsa, OK, USA). Data
were tested for normality and homogeneity of variance
assumptions according to the Shapiro-Wilk’s test and Levene’s
test, respectively. Groups that met the assumptions (para-
metric data) were compared by applying a t test or one-way
ANOVA followed by Tukey’s post hoc test. Those groups that
did not meet the assumptions (nonparametric data) were
compared using the Mann-Whitney or Kruskal-Wallis test
followed by Dunn’s post hoc test. Data were expressed as
mean ± standard deviation and 𝑝 < 0.05 was considered
statistically significant.
Correlation tests were conducted (Pearson’s test for para-
metric data and Spearman’s test for nonparametric data)
between the levels of lipid peroxidation (MDA) and the
activity of CAT, GST, and GPX, using Statistica 9.0 software
(Statsoft Inc.).
3. Results
3.1. Biometric Parameters and Glycaemia. The body weights
were, respectively, ∼16 and ∼42% lower (𝑝 ≤ 0.001) after one
week (D1) or two months of diabetes (D2), compared to the
control groups (Table 1).TheMLT treatment did not affect the
body weight of normal rats or the body weight loss in diabetic
groups (Table 1).
The ingestion of low doses of MLT also did not influence
the weight of the prostate of healthy rats (Table 1). Such
treatment avoided the prostatic atrophy induced by short-
term diabetes, but not by the long-term treatment (Table 1;
𝑝 ≤ 0.05).
In both experiments, the testicular weight was not
affected by diabetes independent of treatment with MLT
(Table 1). The epididymal weight was higher in the M1 group
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Table 1:Themean and standard deviation of body, prostate, testis, and epididymiswet weight and blood glucose levels of short- and long-term
experimental groups.
C1 M1 D1 MD1
Body weight (g) 383.27 ± 39.92a 390.85 ± 66.88a 320.94 ± 46.91b 293.85 ± 28.67b
Prostate weight (mg) 371.57 ± 36.04a 346.1 ± 42.28a,b 288.53 ± 68.19b 328.68 ± 82.24a,b
Testis weight (g) 1.694 ± 0.10a,b 1.795 ± 0.22a 1.629 ± 0.19a,b 1.570 ± 0.09b
Epididymis (mg) 540.86 ± 0.06a,b,c 590.39 ± 0.09a 494.22 ± 0.11b,c 496.58 ± 0.06c
Blood glucose levels (mg/dL) 111.21 ± 33.10a 102.85 ± 16.63a 359.66 ± 79.48b 404.18 ± 32.36b
C2 M2 D2 MD2
Body weight (g) 451.71 ± 16.14A# 450.57 ± 40.72A,C∗ 259.66 ± 14.22B# 295.2 ± 59.33B,C
Prostate weight (mg) 613.4 ± 89.0A∗ 543.33 ± 67.58A∗ 219.6 ± 50.53B 231.5 ± 34.88B∗
Testis weight (g) 1.812 ± 0.09A∗ 1.701 ± 0.21A 1.603 ± 0.24A 1.504 ± 0.30A
Epididymis (mg) 728.64 ± 0.05A∗ 612.35 ± 0.15A,B 466.04 ± 0.05B 733.75 ± 0.17A,B∗
Blood glucose levels (mg/dL) 87.85 ± 11.12A# 89 ± 9.05A 491.16 ± 56.55B∗ 483.4 ± 84.2B∗
C1: one-week control; M1: one-week control treated with melatonin; D1: one-week diabetic; MD1: one-week diabetic treated with melatonin; C2: two-
month control; M2: two-month control treated with melatonin; D2: two-month diabetic; MD2: two-month diabetic treated with melatonin (𝑁 = 10
animals/group). ∗Different lowercase letters indicate statistical differences among short-term experimental groups (parametric data: prostate and epididymis
weight; nonparametric data: body and testis weight and blood glucose levels). Different uppercase letters indicate statistical differences among long-term
experimental groups (parametric data: prostateweight; nonparametric data: body, testis and epididymisweight, and blood glucose levels). ∗Indicates a statistical
difference between experimental periods (parametric data). #Indicates a statistical difference between experimental periods (nonparametric data).
compared to the diabetic groups (Table 1; 𝑝 ≤ 0.004).
Diabetes reduced the epididymal weight in both experiments
(Table 1; 𝑝 ≤ 0.04). Despite the higher epididymal atrophy
confirmed in long-term diabetes, the MLT treatment pre-
vented this atrophy (Table 1).
Animals showed blood glucose levels that were about
three and six times higher after short- or long-term diabetes,
respectively, than that in the control groups (𝑝 ≤ 0.001),
regardless of MLT treatment (Table 1). Administration of
MLT did not affect the glucose level homeostasis of groups
M1 and M2.
3.2. CATActivity. TheCAT activity in the blood (Figure 2(a))
increased by about 40% in 21-week-old rats in comparison
to the 14-week-old rats but did not change among the
groups in both experiments. In the ventral prostate, the
CAT activity (Figure 2(b)) was unchanged in the groups
of the first experiment, but doubled after two months of
diabetes compared with the control group and this increase
was prevented by MLT treatment. The levels of testicular
CAT were higher in the groups of long-term experiment
(Figure 2(c), 𝑝 ≤ 0.04). Melatonin had an inhibitory effect
on testis CAT activity in long-term diabetes (Figure 2(c)).
Similar to the testis, the activity of CAT in the epididymis of
21-week-old rats was also higher in comparison to those of
14-week-old healthy rats (𝑝 ≤ 0.04; Figure 2(c) and 𝑝 ≤ 0.01;
Figure 2(d), resp.).
3.3. GST Activity. GST was the only biomarker of oxidative
stress that changed in the blood after short-term diabetes
(Figure 3(a)). The GST activity increased during short-term
diabetes (𝑝 = 0.0042) and this rise was partially prevented
in the MLT-treated group (Figure 3(a)); however, blood GST
activity decreased (𝑝 = 0.0007) during long-term diabetes,
regardless of the MLT treatment (Figure 3(a)). The blood
GST activity increased in 21-week-old groups in comparison
to younger groups (𝑝 ≤ 0.001). Prostatic GST activity
(Figure 3(b)) also increased after the onset of diabetes (𝑝 =
0.0186), and MLT administration prevented this increase
only in the long-term experiment. The GST activity was not
affected in testis and epididymis among the animals of short
and long-term experimental groups (Figure 3(d)); however
the activity of this enzymewas decreased in the epididymis of
older healthy rats, regardless of MLT treatment (Figure 3(d)).
3.4. GPx Activity. The GPx activity in blood had an inverse
behavior to GST (Figure 4(a)); that is, the activity was
unchanged during short-term diabetes and increased twofold
after two months of diabetes compared to the control group,
independent of MLT treatment. In the prostate gland, GPx
activity increased ∼70% one week after the onset of diabetes
and MLT normalized this value in the MD1 group; how-
ever, it was unaffected in groups of the longer experiment
(Figure 4(b)).The activity of this antioxidant enzyme in testis
was not altered neither in experimental diabetes nor mela-
tonin treatment (Figure 4(c)). There was an increase in GPx
activity in the epididymis of healthy rats after MLT treatment
in comparison to those in the control group (Figure 4(d);
𝑝 = 0.007). Moreover, the epididymis GPx activity was very
low in the two-month experiment (Figure 4(d)).
3.5. Lipid Peroxidation. In blood, the MDA levels were
unchanged in the groups of the short-term experiment
(Figure 5(a)) and increased after two months of untreated
diabetes (𝑝 = 0.038), regardless of MLT treatment. Diabetes
did not affect lipid peroxidation in prostate (Figure 5(d)),
either in the short-term or in long-term, but MLT treatment
reduced by 50% the lipid peroxidation levels of long-term
diabetic rats in comparison with untreated diabetic group
(Figure 5(b)). Besides that, prostatic MDA levels were higher
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Figure 2: Catalase activity (U/mg protein) in blood (a), prostate (b), testis (c), and epididymis (d) of short- and long-term experiments.
C1: one-week control; M1: one-week control treated with melatonin; D1: one-week diabetic; MD1: one-week diabetic treated with melatonin;
C2: two-month control; M2: two-month control treated with melatonin; D2: two-month diabetic; MD2: two-month diabetic treated with
melatonin (𝑁 = 10 animals/group). Different lowercase letters indicate statistical differences among short-term experimental groups
(parametric data: (a), (b), (c), and (d)). Different uppercase letters indicate statistical differences among long-term experimental groups
(parametric data: (a) and (d); nonparametric data: (b) and (c)). ∗ Indicates a statistical difference between experimental periods (parametric
data). # Indicates a statistical difference between experimental periods (nonparametric data).
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Figure 3: Glutathione-S-transferase activity (U/mg protein) in blood (a), prostate (b), testis (c), and epididymis (d) extracts. C1: one-week
control; M1: one-week control treated with melatonin; D1: one-week diabetic; MD1: one-week diabetic treated with melatonin; C2: two-
month control; M2: two-month control treated with melatonin; D2: two-month diabetic; MD2: two-month diabetic treated with melatonin
(𝑁 = 10 animals/group). Different lowercase letters indicate statistical differences among short-term experimental groups (nonparametric
data: (a), (b), (c), and (d)). Different uppercase letters indicate statistical differences among long-term experimental groups (parametric data:
(c) and (d); nonparametric data: (a) and (b)). ∗ Indicates a statistical difference between experimental periods (parametric data). # Indicates
a statistical difference between experimental periods (nonparametric data).
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Figure 4: Glutathione peroxidase activity (U/mg protein) in blood (a), ventral prostate (b), testis (c), and epididymis (d) of rats. C1: one-
week control; M1: one-week control treated with melatonin; D1: one-week diabetic; MD1: one-week diabetic treated with melatonin; C2: two-
month control; M2: two-month control treated with melatonin; D2: two-month diabetic; MD2: two-month diabetic treated with melatonin
(𝑁 = 10 animals/group). Different lowercase letters indicate statistical differences among short-term experimental groups (parametric data:
(c); nonparametric data: (a), (b), and (d)). Different uppercase letters indicate statistical differences among long-term experimental groups
(parametric data: (b), (c), and (d); nonparametric data: (a)). # Indicates a statistical difference between experimental periods (nonparametric
data).
in all groups of the long-term experiment compared to
the short-term groups (𝑝 ≤ 0.04). The testicular levels of
MDA were lower (𝑝 ≤ 0.01) in the groups of the long-
term experiment (Figure 5(c)) whereas in the epididymis, the
peroxidation levels were high in these groups (Figure 5(d);
𝑝 ≤ 0.04).
3.6. Correlation Tests. There was an inverse correlation
between lipid peroxidation and GST activity in both short-
(𝑟 = −0.477; 𝑝 < 0.05) and long-term experiments (𝑟 =
−0.669; 𝑝 < 0.05), in blood (Figures 3(a) and 5(a)). The
increase in GPx activity was directly proportional to the
increase in plasma levels ofMDAafter twomonths of diabetes
(𝑝 < 0.05 and 𝑟 = 0.74; Figures 4(a) and 5(a)).
In the prostate, the rise in GST activity after one week
of diabetes correlated inversely with the decrease in prostatic
MDA levels (𝑟 = −0.604; 𝑝 = 0.022, Figures 3(b) and 5(b)).
4. Discussion
In the present study, we delineate the comparative oxidative
status in three important reproductive organs in terms of
acute and chronic response to streptozotocin-induced dia-
betes, based on the activity of the major antioxidant enzymes
and quantification of lipid peroxidation. In addition, we
analyzed the effects of preadministration and prolonged use
of low MLT doses on the antioxidant system of these organs
and its influence on alterations caused by experimentally
induced diabetes. However it is worthwhile to mention that
the provision of melatonin in the drinking water, although
less stressful and adequate for long-term experiments, was
a limitation for this study since there is no way to know
the exact amount of MLT that was ingested by each animal
as well as the changes in the daily rhythm of this hormone
throughout the experiment. Rasmussen et al. using a similar
experimental protocol [49] verified that rats drank more
than 90% of their total daily water during the dark period
resulting in higher melatonin levels during the night (150.5±
19.2 pg/mL against 24.1±8.8 pg/mLof control) but not in day-
time (14.1 ± 2.6 pg/mL against 11.5 ± 0.00 pg/mL of control).
As we used the same model of melatonin administration as
Rasmussen et al. [49], we assume that the animals exhibited a
comparable pattern of melatonin consumption and probably
exhibited elevation in the levels of this hormone in dark
period.
The biochemical analysis of the antioxidant system from
healthy rats revealed that after 14 weeks of age, the prostate
exhibited higher CAT and GST activities compared to the
testis and epididymis. However, for 21-week-old rats, similar
levels of antioxidant enzyme activities were detected among
the three reproductive organs, with the exception of a higher
GPx activity in the prostate. Therefore, biochemical analysis
indicates that the levels of antioxidant enzyme activity were
maintained in the prostate after a two-month interval, which
was accomplished by an increase in lipid peroxidation in
the gland. In contrast, the testis and epididymis showed an
increase in CAT activity during aging. For the epididymis, the
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Figure 5: Lipid peroxidation quantified by MDA levels in plasm ((a), 𝜇mol/mL plasm) and in extracts (U/mg protein) of prostate (b),
testis (c), and epididymis (d). C1: one-week control; M1: one-week control treated with melatonin; D1: one-week diabetic; MD1: one-week
diabetic treated withmelatonin; C2: two-month control; M2: two-month control treated withmelatonin; D2: two-month diabetic; MD2: two-
month diabetic treated with melatonin (𝑁 = 10 animals/group). Different lowercase letters indicate statistical differences among short-term
experimental groups (parametric data: (b), (c), and (d); nonparametric data: (a)). Different uppercase letters indicate statistical differences
among long-term experimental groups (parametric data: (d); nonparametric data: (a), (b), and (c)).∗ Indicates a statistical difference between
experimental periods (parametric data). # Indicates a statistical difference between experimental periods (nonparametric data).
increase in CAT activity was accompanied by a decrease in
GST and GPx activity. Taken together these findings might
explain the higher susceptibility to oxidative stress of the
prostate during aging, in comparison to testis and epididymis
as indicated by the increase in MDA levels. These data also
reinforce the organ specificity of antioxidant defense and the
existence of compensatory mechanisms during aging.
The experimental protocol used here for the induction
of type I diabetes is widely accepted, and most diabetic rats
exhibited glucose levels above 360mg/dL. As expected, a
drastic reduction in body weight was observed, mainly in
animals with chronic untreated diabetes. The body weight or
blood glucose levels of normal rats were not affected by MLT
treatment. Even in short-term diabetes, MLT ingestion did
not normalize the glycemia or ameliorate the severe weight
loss, as previously observed with doses above 10mg/kg b.w.
[28, 50, 51]. Some studies with experimental diabetes, includ-
ing those with high doses of MLT, showed a normalization
of blood glucose levels [40, 52]; however, this effect of MLT
has been clearly reported for obese rodents in which there is
an improvement in insulin sensitivity [43, 53]. Furthermore,
MLT increases the metabolic activity of brown adipose tissue
[54] which might favor weight loss in diabetic animals.
Streptozotocin-induced diabetes caused atrophy in the
prostate and epididymis. The atrophy of these androgen-
dependent organs was expected, since diabetes leads to
androgen withdrawal [55, 56] and has been reported in
previous studies using similar protocols for diabetes induc-
tion [28, 32, 57]. Some reports indicate a decrease in
the relative testicular weight within three weeks of experi-
mentally induced diabetes, but thereafter, testicular atrophy
is no longer conspicuous [24, 57] and a similar variation was
observed here, although this was not statistically significant.
Treatment with MLT mitigated prostate atrophy induced
by diabetes in the short-term, whereas an opposite effect
was observed for the epididymis, where atrophy after short-
term diabetes was not prevented, but maintenance of wet
weight for long-term diabetic rats was observed. Results of
our laboratory demonstrated thatmaintenance of epididymal
weight by MLT after long-term diabetes was due to higher
sperm counts in this organ (unpublished data).
The biochemical assays indicated that the prostate exhib-
ited a more pronounced antioxidant system response to dia-
betes than the epididymis and testis, which were practically
unresponsive. Our data demonstrate that GST participates in
all phases of prostatic tissue in response to disease but early
responses also involve the activation of GPx, whereas CAT
activation occurs at later stages of untreated diabetes. The
early activation of prostate antioxidant enzymes in response
to acute diabetes in comparison to the unresponsiveness
of the epididymis and testis raises several questions. This
response could be due to a higher sensitivity of the prostate
to streptozotocin, which is known to potentially generate
free radicals [58] and might result in a direct prooxidant
effect on this gland. The prostate blood barrier acts to
restrict leukocyte passage into the prostatic lumen under
inflammatory conditions [59]; however, the permeability of
this barrier to ROS is not well known. It is also possible that
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the prostate antioxidant system is vulnerable to androgen
regulation, as shown by in vitro studies [60], and also to the
hyperglycemic status [32].
Our findings emphasize that GST is an important com-
ponent in the defense against oxidative damage in the
prostate. These findings agree with previous data that report
a pivotal role of GST isoforms in the healthy prostate and in
disease progression [61, 62]. The GSTP1 gene, which encodes
the pi-class glutathione S-transferase, is a defense against
oxidative damage to the genome and is expressed in high
levels by epithelial cells in proliferative inflammatoryAtrophy
(PIA) [61–63], which are considered to be precursors of
premalign and malign prostate lesions. The expression of
GSTP1 is impaired in prostatic epithelial neoplasia (PIN)
and neoplastic lesions, due to somatic “CpG island” DNA
methylation changes [60, 63–65]. Such cells become vulner-
able to oxidants and electrophiles, which result in genome
damage. Furthermore, studies with transplants of tumor-cell
lines demonstrated that the use of Gst-pi-siRNA suppressed
the cell proliferation rate and high levels of intracellular
ROS occurred in the Gst-pi knockout [63]. Experimental
data from our laboratory have shown that the progression
of aloxan-induced diabetes can lead to prostatic atrophy and
neoplastic lesions in rats [18]. Previous studies regarding
medium-term experimental diabetes showed that GST levels
increased in the diabetic group and were reduced by vitamin
C supplementation, which also restored rates of apoptosis
in the prostate [32]. In this context, MLT treatment during
diabetes prevented the increase in prostate GST, which might
indicate a protective action of this neurohormone in the
gland, even at low doses.
The assessment of blood-stress biomarkers was per-
formed, to infer the systemic oxidative status. As expected,
the lipid peroxidation rate indirectly demonstrated a rise in
reactive oxygen species in chronic diabetes. Lipid peroxi-
dation culminates in reduced membrane fluidity, increased
nonspecific permeability, and the activation of membrane
enzymes [66].The results here and previous data [32] indicate
that blood CAT activities are not altered by diabetes. In
addition, they demonstrate the involvement of GST in the
short-term systemic response and the suppression of its
action at later stages of disease, whereas GPx exhibited the
opposite behavior, with a more important role at later stages.
Both GST and GPx appeared to be effective in avoiding the
increase in oxidative stress due to high glucose levels, and,
therefore, the levels of plasma lipid peroxidation correlated
with the activity of these biomarkers although this inverse
correlation was weak for MDA and GST levels.
As previously mentioned, unlike in the prostate, the
response of the epididymis and testes to diabetes did not
involve an increase in antioxidant enzyme activity. These
results differed from data of Shrilatha and Muralidhara [28],
who observed significant changes in testicular antioxidant
enzymes in diabetic rats on the fifth day of exposure to the
disease. These discrepancies are presumably due to small
differences in streptozotocin doses, the age of the animals
used, and the duration of the experiment, since this study
consisted of eight weeks of experimental diabetes, compared
with six weeks in that of Shrilatha and Muralidhara [28].
Surprisingly, lipid peroxidation was not affected in the testis
after two months of diabetes. An increase in MDA levels
was reported by Shrilatha and Muralidhara [28] in testicular
mitochondria during the progression of diabetes, but no such
increase for the testicular microsomal fraction was observed.
This difference can be explained by the protective effect of
the hematotesticular barrier and also by the existence of
other oxidative stress protection mechanisms. Furthermore,
our method of MDA extraction was performed using total
testis homogenates, not in mitochondria and microsoma as
in Shrilatha and Muralidhara [28]. Spermatozoa are very
vulnerable to oxidative stress, as its polyunsaturated fatty
acids in the cell membrane and nuclear and mitochondrial
DNA are susceptible to oxidization [67, 68]. Furthermore,
spermatozoa are very poor in free radicals scavengers [31].
The process of steroidogenesis produces ROS largely from the
mitochondrial respiration chain and the catalytic reactions
of the steroidogenic cytochrome P450 enzymes [69, 70].
Otherwise, within in the testis, sperm is reasonably protected
from oxidative stress by the microenvironment generated
by the Sertoli cells [71]. For these reasons, it is reasonable
to assume that the testis provides an environment that is
relatively well protected against oxidative stress, as observed
here.
Spermmaturation in the epididymis necessitates a certain
level of oxidation, because ROS appear to be key modulators
of the early signal transduction mechanisms that lead to
capacitation [72]. Thus, a fine equilibrium between benefi-
cial oxidation and detrimental oxidative damage has to be
maintained in the epididymal environment [73]. Previous
reports indicated that CAT does not appear to be a major
participant in the control of oxidative stress in this organ
[74], whereas GPx have been implicated in this process [75]
and its expression is regulated by androgens [76]. Except
for the increase of GPx activity in epididymis of healthy
rats treated with MLT for 9 weeks, our data indicated no
marked variations in activity of antioxidant enzymes and
lipid peroxidation levels under diabetes and reinforce the
importance of fine adjustment of epididymal antioxidant
system [72, 73] and its resilience to experimental diabetes.
Several studies have demonstrated the protective action
of MLT against ROS during aging in various organs [77–
79]; however, there is no information concerning organs of
the male genital system. These biochemical assays indicated
that treatment with low MLT doses did not affect changes
in the antioxidant system during aging, except for a discrete
reduction in CAT activity in the epididymis.
The present research demonstrates that hyperglycemia
can adversely affect the antioxidant defense of blood and tis-
sue extracts, particularly of the prostate. The antioxidant sys-
tem of the testis and epididymis is less vulnerable to diabetes
effects and is probably related to intrinsic characteristics of
histophysiology and to the expression pattern of antioxidant
enzymes.TheMLT treatmentmitigated the rise in bloodGST
activity during the early phase of diabetes. This treatment
was more effective for the prostate, mainly in the longer
experiment, as demonstrated by normalization of CAT and
GST activities and MDA levels. Glutathione-S-transferase
proved to be a good marker of compensatory antioxidant
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defense in the ventral prostate, corroborating our previous
data on medium-term diabetes. Melatonin normalized the
activities of antioxidant enzymes in the prostate, even at low
doses, which demonstrates its effective antioxidant role in this
organ.
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